Celsion Corporation Company Profile (NASDAQ:CLSN)

About Celsion Corporation (NASDAQ:CLSN)

Celsion Corporation logoCelsion Corporation is an oncology drug development company. The Company's product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study). Its pipeline also includes GEN-1, a deoxyribonucleic acid (DNA) mediated immunotherapy for the localized treatment of ovarian and brain cancers. It has over three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, including Lysolipid Thermally Sensitive Liposomes, a heat sensitive liposomal based dosage form that targets disease with known therapeutics in the presence of mild heat; TheraPlas, a nucleic acid-based treatment for local transfection of therapeutic plasmids, and TheraSilence, a systemic dosage form for lung directed anti-cancer ribonucleic acid (RNA).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CLSN
  • CUSIP: N/A
  • Web: www.celsion.com
Capitalization:
  • Market Cap: $13.03 million
  • Outstanding Shares: 8,351,000
Average Prices:
  • 50 Day Moving Avg: $1.40
  • 200 Day Moving Avg: $1.20
  • 52 Week Range: $0.19 - $4.96
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.44
  • P/E Growth: 0.0000
Sales & Book Value:
  • Annual Revenue: $500,000.00
  • Price / Sales: 25.04
  • Book Value: $1.12 per share
  • Price / Book: 1.33
Profitability:
  • EBIDTA: ($18,990,000.00)
  • Net Margins: -4,440.60%
  • Return on Equity: -276.51%
  • Return on Assets: -64.50%
Debt:
  • Current Ratio: 0.54%
  • Quick Ratio: 0.54%
Misc:
  • Average Volume: 623,419 shs.
  • Beta: 1
  • Short Ratio: 0.5
 

Frequently Asked Questions for Celsion Corporation (NASDAQ:CLSN)

What is Celsion Corporation's stock symbol?

Celsion Corporation trades on the NASDAQ under the ticker symbol "CLSN."

When did Celsion Corporation's stock split? How did Celsion Corporation's stock split work?

Celsion Corporation shares reverse split on the morning of Tuesday, May 30th 2017. The 1-14 reverse split was announced on Friday, May 26th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 26th 2017. An investor that had 100 shares of Celsion Corporation stock prior to the reverse split would have 7 shares after the split.

How were Celsion Corporation's earnings last quarter?

Celsion Corporation (NASDAQ:CLSN) issued its quarterly earnings results on Thursday, May, 18th. The company reported ($1.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.30) by $0.34. The company earned $0.13 million during the quarter, compared to analyst estimates of $0.13 million. Celsion Corporation had a negative net margin of 4,440.60% and a negative return on equity of 276.51%. View Celsion Corporation's Earnings History.

When will Celsion Corporation make its next earnings announcement?

Celsion Corporation is scheduled to release their next quarterly earnings announcement on Thursday, November, 9th 2017. View Earnings Estimates for Celsion Corporation.

Where is Celsion Corporation's stock going? Where will Celsion Corporation's stock price be in 2017?

3 equities research analysts have issued 1 year target prices for Celsion Corporation's shares. Their forecasts range from $21.00 to $56.00. On average, they expect Celsion Corporation's share price to reach $32.67 in the next twelve months. View Analyst Ratings for Celsion Corporation.

What are analysts saying about Celsion Corporation stock?

Here are some recent quotes from research analysts about Celsion Corporation stock:

  • 1. According to Zacks Investment Research, "Celsion is dedicated to the development and commercialization of oncology drugs including tumor-targeting treatments using focused heat energy in combination with heat activated drug delivery systems. Celsion has research, license or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, North Shore Long Island Jewish Health System. " (8/29/2017)
  • 2. Maxim Group analysts commented, "Celsion announced that the company will present updated data from the P1b Ovation study evaluating GEN-1 (DNA-based IL-12) in advanced ovarian cancer at ASCO (American Society of Clinical Oncology, June 2-6, 2017)." (4/20/2017)

Who are some of Celsion Corporation's key competitors?

Who are Celsion Corporation's key executives?

Celsion Corporation's management team includes the folowing people:

  • Jeffrey Wayne Church CPA, Chief Financial Officer, Senior Vice President, Corporate Secretary, IR Contact Officer
  • Khursheed Anwer Ph.D., Executive Vice President, Chief Scientific Officer - Nucleic Acid Therapy
  • Nicholas Borys M.D., Senior Vice President and Chief Medical Officer
  • Michael H. Tardugno, Executive Chairman of the Board, President, Chief Executive Officer
  • Donald Braun Ph.D., Independent Director
  • Pok Yu Chow Ph.D., Independent Director
  • Frederick J. Fritz, Independent Director
  • Robert W. Hooper, Independent Director
  • Alberto R. Martinez M.D., Independent Director

Who owns Celsion Corporation stock?

Celsion Corporation's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include ANSON FUNDS MANAGEMENT LP (9.60%), INTRACOASTAL CAPITAL, LLC (8.30%), INTRACOASTAL CAPITAL, LLC (1.90%), Vanguard Group Inc. (2.28%), INTRACOASTAL CAPITAL, LLC (1.50%) and Virtu KCG Holdings LLC (1.24%). Company insiders that own Celsion Corporation stock include Alberto R Martinez Jr, Egwu, Inc Fka Egen, Inc, Frederick J Fritz and Michael H Tardugno. View Institutional Ownership Trends for Celsion Corporation.

Who sold Celsion Corporation stock? Who is selling Celsion Corporation stock?

Celsion Corporation's stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc. and Virtu KCG Holdings LLC. View Insider Buying and Selling for Celsion Corporation.

How do I buy Celsion Corporation stock?

Shares of Celsion Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Celsion Corporation's stock price today?

One share of Celsion Corporation stock can currently be purchased for approximately $1.50.


MarketBeat Community Rating for Celsion Corporation (NASDAQ CLSN)
Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  180 (Vote Outperform)
Underperform Votes:  106 (Vote Underperform)
Total Votes:  286
MarketBeat's community ratings are surveys of what our community members think about Celsion Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Celsion Corporation (NASDAQ:CLSN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 2 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $32.67 (2,078.79% upside)

Analysts' Ratings History for Celsion Corporation (NASDAQ:CLSN)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/15/2017Maxim GroupReiterated RatingHoldMediumView Rating Details
4/10/2017Rodman & RenshawReiterated RatingBuy$21.00HighView Rating Details
4/10/2017HC WainwrightReiterated RatingBuy$21.00HighView Rating Details
11/24/2015Cantor FitzgeraldReiterated RatingNot Available -> BuyN/AView Rating Details
(Data available from 9/21/2015 forward)

Earnings

Earnings History for Celsion Corporation (NASDAQ:CLSN)
Earnings by Quarter for Celsion Corporation (NASDAQ:CLSN)
Earnings History by Quarter for Celsion Corporation (NASDAQ CLSN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2017        
5/18/2017Q1 2017($1.30)($1.64)$0.13 million$0.13 millionViewN/AView Earnings Details
3/16/2017Q4 2016($2.24)($1.96)$0.13 million$0.13 millionViewN/AView Earnings Details
11/10/2016Q3 2016($2.66)($3.22)$0.13 million$0.13 millionViewN/AView Earnings Details
8/15/2016Q2($2.94)($2.66)$0.13 million$0.13 millionViewListenView Earnings Details
5/16/2016Q116($2.94)($3.36)$0.13 million$0.13 millionViewListenView Earnings Details
3/30/2016Q415($3.36)($3.36)$0.16 million$0.13 millionViewListenView Earnings Details
11/5/2015Q315($3.64)($2.80)$0.14 million$0.13 millionViewN/AView Earnings Details
8/10/2015Q215($4.34)($3.78)$0.16 million$0.13 millionViewListenView Earnings Details
5/12/2015Q1($4.62)($4.76)$0.13 million$0.13 millionViewN/AView Earnings Details
3/12/2015Q4 2014($5.04)($4.48)$0.13 million$0.13 millionViewN/AView Earnings Details
11/11/2014Q3 2014($4.20)($4.90)$0.16 million$0.13 millionViewN/AView Earnings Details
8/7/2014Q214($3.92)($4.48)$0.13 million$0.13 millionViewN/AView Earnings Details
5/8/2014Q1 2014($2.80)($4.62)$0.13 million$0.13 millionViewN/AView Earnings Details
3/13/2014($3.92)($2.66)ViewN/AView Earnings Details
11/12/2013Q3($3.15)($4.20)$0.13 millionViewListenView Earnings Details
8/8/2013Q2 2013($0.98)$0.14$0.13 millionViewN/AView Earnings Details
5/9/2013Q1 2013($2.24)($1.68)ViewN/AView Earnings Details
11/12/2012Q312($2.38)($2.52)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Celsion Corporation (NASDAQ:CLSN)
2017 EPS Consensus Estimate: ($0.98)
2018 EPS Consensus Estimate: ($1.06)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.08)($0.08)($0.08)
Q2 20171($0.08)($0.08)($0.08)
Q3 20171($0.43)($0.43)($0.43)
Q4 20171($0.39)($0.39)($0.39)
Q1 20181($0.32)($0.32)($0.32)
Q2 20181($0.24)($0.24)($0.24)
Q3 20181($0.25)($0.25)($0.25)
Q4 20181($0.25)($0.25)($0.25)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Celsion Corporation (NASDAQ:CLSN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Celsion Corporation (NASDAQ:CLSN)
Insider Ownership Percentage: 3.80%
Institutional Ownership Percentage: 7.47%
Insider Trades by Quarter for Celsion Corporation (NASDAQ:CLSN)
Institutional Ownership by Quarter for Celsion Corporation (NASDAQ:CLSN)
Insider Trades by Quarter for Celsion Corporation (NASDAQ:CLSN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/7/2017Frederick J FritzDirectorBuy13,000$1.89$24,570.00View SEC Filing  
2/21/2017Alberto R Martinez JrDirectorBuy35,000$0.23$8,050.00View SEC Filing  
2/15/2017Alberto R Martinez JrDirectorBuy45,000$0.22$9,900.00View SEC Filing  
11/14/2016Alberto R Martinez JrDirectorBuy10,000$0.86$8,600.00View SEC Filing  
11/11/2016Alberto R Martinez JrDirectorBuy10,000$0.91$9,100.00View SEC Filing  
10/7/2016Michael H TardugnoChairmanBuy10,000$1.14$11,400.00View SEC Filing  
8/16/2016Alberto R Martinez JrDirectorBuy5,000$1.25$6,250.00View SEC Filing  
6/17/2016Alberto R Martinez JrDirectorBuy5,000$1.35$6,750.00View SEC Filing  
6/16/2016Michael H TardugnoCEOBuy7,500$1.35$10,125.00View SEC Filing  
2/19/2016Michael H TardugnoCEOBuy3,000$1.27$3,810.00View SEC Filing  
2/17/2016Michael H TardugnoCEOBuy2,000$1.27$2,540.00View SEC Filing  
2/16/2016Alberto R Martinez JrDirectorBuy5,000$1.16$5,800.00View SEC Filing  
2/16/2016Michael H TardugnoCEOBuy4,500$1.20$5,400.00View SEC Filing  
2/12/2016Michael H TardugnoCEOBuy6,500$1.13$7,345.00View SEC Filing  
12/3/2015Egwu, Inc. Fka Egen, Inc.Major ShareholderSell5,556$2.08$11,556.48View SEC Filing  
11/30/2015Egwu, Inc. Fka Egen, Inc.Major ShareholderSell20,000$2.15$43,000.00View SEC Filing  
9/8/2015Egwu, Inc. Fka Egen, Inc.Major ShareholderSell10,000$2.11$21,100.00View SEC Filing  
8/17/2015Egwu, Inc. Fka Egen, Inc.Major ShareholderSell10,000$2.19$21,900.00View SEC Filing  
8/13/2015Egwu, Inc. Fka Egen, Inc.Major ShareholderSell20,000$2.23$44,600.00View SEC Filing  
5/13/2015Alberto R Martinez JrDirectorBuy5,000$2.50$12,500.00View SEC Filing  
12/18/2014Frederick J FritzDirectorBuy4,000$2.34$9,360.00View SEC Filing  
11/13/2014Robert W HooperDirectorBuy4,000$2.50$10,000.00View SEC Filing  
8/15/2014Alberto R Martinez JrDirectorBuy5,000$3.12$15,600.00View SEC Filing  
8/15/2014Michael H TardugnoCEOBuy4,000$3.12$12,480.00View SEC Filing  
8/14/2014Frederick J FritzDirectorBuy4,000$3.20$12,800.00View SEC Filing  
6/26/2014Alberto R Martinez JrDirectorBuy5,000$3.36$16,800.00View SEC Filing  
6/11/2014Michael H TardugnoCEOBuy5,000$3.20$16,000.00View SEC Filing  
3/14/2014Frederick FritzDirectorBuy2,500$3.86$9,650.00View SEC Filing  
3/14/2014Michael TardugnoCEOBuy4,000$3.84$15,360.00View SEC Filing  
11/19/2013Michael TardugnoCEOBuy2,800$3.59$10,052.00View SEC Filing  
11/15/2013Frederick FritzDirectorBuy3,000$3.80$11,400.00View SEC Filing  
8/16/2013Frederick FritzDirectorBuy10,000$1.09$10,900.00View SEC Filing  
8/16/2013Michael TardugnoCEOBuy5,000$1.08$5,400.00View SEC Filing  
6/12/2013Michael H TardugnoCEOBuy10,000$1.35$13,500.00View SEC Filing  
5/21/2013Alberto R Martinez JrDirectorBuy5,000$0.93$4,650.00View SEC Filing  
5/13/2013Alberto R Martinez JrDirectorBuy5,000$0.96$4,800.00View SEC Filing  
5/10/2013Alberto R Martinez JrDirectorBuy5,000$0.92$4,600.00View SEC Filing  
3/20/2013Alberto R Martinez JrDirectorBuy3,750$1.06$3,975.00View SEC Filing  
12/10/2012Max LinkDirectorBuy14,000$7.60$106,400.00View SEC Filing  
11/15/2012Robert W HooperDirectorBuy11,600$5.20$60,320.00View SEC Filing  
9/14/2012Michael H TardugnoCEOBuy5,000$5.03$25,150.00View SEC Filing  
9/10/2012Robert W HooperDirectorBuy10,000$4.95$49,500.00View SEC Filing  
8/29/2012Robert W HooperDirectorBuy2,500$4.65$11,625.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Celsion Corporation (NASDAQ:CLSN)
Latest Headlines for Celsion Corporation (NASDAQ:CLSN)
Source:
DateHeadline
finance.yahoo.com logoETFs with exposure to Celsion Corp. : September 18, 2017
finance.yahoo.com - September 18 at 10:24 PM
finance.yahoo.com logoStocks Near 52-Week Lows: 4 Attractive Picks
finance.yahoo.com - September 8 at 5:42 PM
finance.yahoo.com logoStocks Near 52-Week Lows: 4 Attractive Picks
finance.yahoo.com - September 8 at 5:42 PM
americanbankingnews.com logoCelsion Corporation (CLSN) Upgraded to Sell at ValuEngine
www.americanbankingnews.com - September 3 at 5:52 PM
finance.yahoo.com logoETFs with exposure to Celsion Corp. : August 31, 2017
finance.yahoo.com - August 31 at 10:13 PM
americanbankingnews.com logoZacks Investment Research Upgrades Celsion Corporation (CLSN) to Buy
www.americanbankingnews.com - August 29 at 8:56 PM
globenewswire.com logoCelsion Announces Presentation of OVATION Study Findings at the Upcoming AACR Special Conference - GlobeNewswire (press release)
globenewswire.com - August 24 at 10:27 PM
finance.yahoo.com logoCelsion Announces Presentation of OVATION Study Findings at the Upcoming AACR Special Conference
finance.yahoo.com - August 24 at 5:23 PM
finance.yahoo.com logoCelsion Corp. :CLSN-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 24 at 5:23 PM
bizjournals.com logoStocks Under Scanner in the Biotech Space -- Merrimack Pharma, MannKind, NeuroDerm, and Celsion
www.bizjournals.com - August 23 at 5:54 PM
bizjournals.com logoStocks Under Scanner in the Biotech Space -- Merrimack Pharma, MannKind, NeuroDerm, and Celsion
www.bizjournals.com - August 23 at 5:54 PM
finance.yahoo.com logoEdited Transcript of CLSN earnings conference call or presentation 15-Aug-17 3:00pm GMT
finance.yahoo.com - August 18 at 5:21 PM
americanbankingnews.com logoQ3 2017 EPS Estimates for Celsion Corporation Increased by Griffin Securities (CLSN)
www.americanbankingnews.com - August 18 at 6:44 AM
seekingalpha.com logoCelsion's (CLSN) CEO Michael Tardugno on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 15 at 11:01 PM
globenewswire.com logoCelsion Corporation Reports Second Quarter 2017 Financial Results and Provides Business Update - GlobeNewswire (press release)
globenewswire.com - August 15 at 11:01 PM
americanbankingnews.com logoMaxim Group Reiterates Hold Rating for Celsion Corporation (CLSN)
www.americanbankingnews.com - August 15 at 6:08 PM
finance.yahoo.com logoCelsion Corporation Reports Second Quarter 2017 Financial Results and Provides Business Update
finance.yahoo.com - August 15 at 5:59 PM
americanbankingnews.com logoCelsion Corporation (NASDAQ:CLSN) Releases Earnings Results
www.americanbankingnews.com - August 14 at 8:23 PM
globenewswire.com logoCelsion Corporation to Hold Second Quarter 2017 Financial Results Conference Call on Tuesday, August 15, 2017 - GlobeNewswire (press release)
globenewswire.com - August 8 at 5:03 PM
feeds.benzinga.com logoCelsion Corporation to Hold Second Quarter 2017 Financial Results Conference Call on Tuesday, August 15, 2017
feeds.benzinga.com - August 8 at 9:37 AM
nasdaq.com logoAQB Reaps A Bounty, CLSN Ends Dual Listing, MNK Opens Wallet ... - Nasdaq
www.nasdaq.com - August 8 at 3:46 AM
streetinsider.com logoCelsion (CLSN) Says DMC Completed Mid-Study Review of Phase III ThermoDox OPTIMA Study in Primary Liver Cancer - StreetInsider.com
www.streetinsider.com - August 8 at 3:46 AM
streetinsider.com logoCelsion (CLSN) Says DMC Completed Mid-Study Review of Phase III ThermoDox OPTIMA Study in Primary Liver Cancer
www.streetinsider.com - August 7 at 5:43 PM
streetinsider.com logoCelsion (CLSN) Says DMC Completed Mid-Study Review of Phase III ThermoDox OPTIMA Study in Primary Liver Cancer
www.streetinsider.com - August 7 at 5:43 PM
finance.yahoo.com logoData Monitoring Committee Completes Mid-Study Review of Celsion’s Phase III ThermoDox® OPTIMA Study in Primary Liver Cancer
finance.yahoo.com - August 7 at 5:43 PM
finance.yahoo.com logoData Monitoring Committee Completes Mid-Study Review of Celsion’s Phase III ThermoDox® OPTIMA Study in Primary Liver Cancer
finance.yahoo.com - August 7 at 5:43 PM
americanbankingnews.com logoMaxim Group Reiterates Hold Rating for Celsion Corporation (NASDAQ:CLSN)
www.americanbankingnews.com - August 7 at 3:38 PM
globenewswire.com logoCelsion Corporation to Delist from the Tel Aviv Stock Exchange - GlobeNewswire (press release)
globenewswire.com - August 4 at 10:38 PM
finance.yahoo.com logoCelsion Corporation to Delist from the Tel Aviv Stock Exchange
finance.yahoo.com - August 4 at 10:38 PM
nasdaq.com logoBUZZ-U.S. STOCKS ON THE MOVE- Apple, Systemax, Pioneer, AMC Entertainment
www.nasdaq.com - August 4 at 4:52 AM
americanbankingnews.com logoCelsion Corporation (CLSN) Scheduled to Post Quarterly Earnings on Thursday
www.americanbankingnews.com - August 3 at 7:16 AM
streetinsider.com logoCelsion (CLSN) Reports Translational Data from OVATION Study in Newly Diagnosed Advanced Ovarian Cancer ... - StreetInsider.com
www.streetinsider.com - August 3 at 4:09 AM
streetinsider.com logoCelsion (CLSN) Reports Translational Data from OVATION Study in Newly Diagnosed Advanced Ovarian Cancer Patients
www.streetinsider.com - August 2 at 6:03 PM
finance.yahoo.com logoCelsion Announces Latest Translational Data from the OVATION Study in Newly Diagnosed Advanced Ovarian Cancer Patients
finance.yahoo.com - August 2 at 6:03 PM
nasdaq.com logoMonday 7/10 Insider Buying Report: NYMX, CLSN
www.nasdaq.com - July 10 at 5:18 PM
seekingalpha.com logoCelsion Carves Itself A New Path
seekingalpha.com - July 10 at 5:18 PM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: Valeant Pharmaceuticals and Celsion Corporation
finance.yahoo.com - July 8 at 9:49 AM
americanbankingnews.com logoCelsion Corporation (NASDAQ:CLSN) Director Buys $24,570.00 in Stock
www.americanbankingnews.com - July 7 at 9:03 PM
nasdaq.com logoCelsion Completes Ovarian Cancer Trial Enrollment, Stock Up - Nasdaq
www.nasdaq.com - July 7 at 4:36 AM
globenewswire.com logoCelsion Corporation Announces $5 Million Registered Direct Offering - GlobeNewswire (press release)
globenewswire.com - July 7 at 4:36 AM
finance.yahoo.com logoCelsion Corporation Announces $5 Million Registered Direct Offering
finance.yahoo.com - July 6 at 6:31 PM
americanbankingnews.com logoCelsion Corporation (NASDAQ:CLSN) Expected to Announce Quarterly Sales of $130,000.00
www.americanbankingnews.com - July 6 at 9:28 AM
finance.yahoo.com logoCelsion Announces Completion of OVATION Study and Provides Update on its Immunotherapy Trial in Advanced Stage III and IV Ovarian Cancer
finance.yahoo.com - July 5 at 11:01 PM
benzinga.com logoMid-Afternoon Market Update: Crude Oil Down 3.8%; Monogram Residential Trust Shares Spike Higher - Benzinga
www.benzinga.com - July 5 at 5:58 PM
benzinga.com logo12 Biggest Mid-Day Gainers For Wednesday | Benzinga - Benzinga
www.benzinga.com - July 5 at 5:58 PM
nasdaq.com logoBUZZ-US STOCKS ON THE MOVE- Tesla, O'Reilly Automotive, Diebold Nixdorf - Nasdaq
www.nasdaq.com - July 5 at 5:58 PM
seekingalpha.com logoCelsion completes OVATION study and provides update on advanced stage III and IV Ovarian Cancer; shares ahead ... - Seeking Alpha
seekingalpha.com - July 5 at 5:58 PM
americanbankingnews.com logoCelsion Corporation (CLSN) Expected to Post Earnings of -$1.18 Per Share
www.americanbankingnews.com - July 4 at 10:30 PM
americanbankingnews.com logoQ1 2018 Earnings Estimate for Celsion Corporation (NASDAQ:CLSN) Issued By Griffin Securities
www.americanbankingnews.com - July 3 at 10:07 AM
americanbankingnews.com logoCelsion Corporation (CLSN) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - June 26 at 10:04 PM

Social

Chart

Celsion Corporation (CLSN) Chart for Thursday, September, 21, 2017

This page was last updated on 9/21/2017 by MarketBeat.com Staff